The V 2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells.
G MarronciniC AnceschiL NaldiB FibbiF BaldanziM MaggiAlessandro PeriPublished in: Journal of endocrinological investigation (2022)
receptor might be considered a possible target in anti-cancer strategies in the future.